On 5/26/2022 Roth Capital brokerage Lowered the Price Target for First Wave BioPharma, Inc. (FWBI) from $600.00 to $270.00 giving a Buy Rating for the stock!
The stock is now at a historic low: $3.31.
In January 2021 it was $788.
Just to reach the Analyst Price Target, it need to grow 81.5X from this level.
The Market cap is extremely low: 4.58 Mil. 81X would...
James Sapirstein
Chairman, President and CEO of First Wave BioPharma, Inc.:
"We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative...
